Expand all sections

Vedolizumab

Entyvio

Extended indication Treatment of adult patients with pouchitis, who have undergone proctocolectomy and ileal pouch anal
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Vedolizumab
Domain Chronic immune diseases
Reason of inclusion Indication extension
Main indication Bowel diseases
Extended indication Treatment of adult patients with pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with, lost response to, or were intolerant to antibiotic therapy.
Proprietary name Entyvio
Manufacturer Takeda
Mechanism of action Immunosuppression
Route of administration Intravenous
Therapeutical formulation Powder for solution for infusion
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date June 2021
Expected Registration March 2022
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Current treatment options anti-TNF, vedolizumab, ustekinumab, tofacitinib.
Therapeutic value No estimate possible yet

Expected patient volume per year

Additional remarks Colitis ulcerosa komt steeds vaker voor met name in de westerse landen. Er zijn momenteel ruim 80.000 mensen in Nederland met een chronische darmontsteking. Dit is ongeveer 1 op de 200 mensen. Hiervan heeft iets meer dan de helft ulcerative colitis.

Expected cost per patient per year

References https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/kostenoverzicht/modal/vedolizumab
Additional remarks Entyvio, 300 mg poeder voor oplossing voor infusie 300 mg: € 2.298,80. Entyvio, 0,68 ml injectievloeistof 158,8 mg/ml: € 658,80

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.